Table 1.
Patient characteristics (n = 161).
| Characteristic | Value | |
|---|---|---|
| Age, years | Median (range) | 67 (38–85) |
| ≥ 75 years, n (%) | 26 (16) | |
| Sex, n (%) | Male | 88 (55) |
| ECOG PS, n (%) | 0 | 74 (46) |
| 1 | 76 (47) | |
| ≥ 2 | 11 (7) | |
| Stage, n (%) | Locally advanced | 19 (12) |
| Metastatic | 142 (88) | |
| History of pancreatomy, n (%) | 40 (25) | |
| History of radiation, n (%) | 5 (3) | |
| History of biliary drainage, n (%) | 41 (26) | |
| Duration time of previous chemotherapy, months | Median (range) | 9.8 (1.4–45.0) |
| Treatment line of Nal-IRI, n (%) | 2nd | 104 (65) |
| 3rd or later | 57 (35) | |
| Previous drugs, n (%) | Gemcitabine | 161 (100) |
| Fluoropyrimidine | 52 (32) | |
| Platinum | 20 (12) | |
| Irinotecan | 18 (11) | |
| Histology, n (%) | Adenocarcinoma | 148 (91) |
| Others | 7 (4) | |
| Uncertified | 6 (4) | |
| Tumor location, n (%) | Head | 67 (42) |
| Body/tail | 94 (58) | |
| Site of metastasis, n (%) | Liver | 89 (55) |
| Peritoneum | 44 (27) | |
| Ascites, n (%) | None | 137 (85) |
| Intrapelvic | 17 (11) | |
| Extrapelvic | 7 (4) | |
| CA19-9, U/ml | Median (range) | 1015 (1–543,522) |
| ≥ 37 U/ml, n (%) | 130 (81) | |
| NLR | Median (range) | 3.16 (0.48–21.86) |
| ≥ 3.16, n (%) | 81 (50) | |
| CAR | Median (range) | 0.079 (0.003–11.542) |
| ≥ 0.079, n (%) | 79 (49) | |
| UGT1A1, n (%) | Wild | 80 (50) |
| -/*6 or -/*28 | 64 (40) | |
| *6/*6, *6/*28 or *28/*28 | 8 (5) | |
| Unknown | 9 (6) | |
| Complication, n (%) | Any | 94 (58) |
| Diabetes | 48 (30) | |
| Hypertension | 37 (23) | |
| Cardiovascular disease | 10 (6) | |
| Stroke | 7 (4) |
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, Nal-IRI nanoliposomal irinotecan, CA19-9 carbohydrate antigen 19–9, NLR neutrophil-to-lymphocyte ratio, CAR C-reactive protein-albumin ratio, UGT1A1 uridine diphosphate glucuronosyltransferase family 1 member A1.